Cancer Research Institute
Clinical Trials
LOXO-RAS-20001: A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors
This study is currently enrolling.
The main purpose of this research study (during both monotherapy and combination therapy evaluation) includes the following: To determine whether LY3537982 is safe; To identify which dose level of LY3537982, by itself or in co ...
MA-GVHD-401: A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)
This study is currently enrolling.
Describe the clinical course and burden of cGVHD after alloSCT. Describe personal and healthcare resource utilization associated with the management of cGVHD. Describe practice patterns and therapy strategies in participants tr ...
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer A032103
This study is currently enrolling.
This study is being done to answer the following question: After having your bladder surgically removed after being diagnosed with bladder cancer, can we better identify which patients need an additional treatment called immuno ...
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol Study Title for Study Participants: Pediatric MATCH screening protocol
This study is currently enrolling.
The main purpose of this study is to learn how well tumors that have specific genetic changes (mutations) respond to drugs that target those changes. This combination of a tumor with a mutation and a drug that aims at that muta ...
NG-350A-02: A multicentre, open-label, non-randomized, phase 1a/1b study of NG-350A, a tumour-selective anti-CD40-expressing adenoviral vector, in combination with pembrolizumab in patients with metastatic or advanced epithelial tumours (FORTIFY)
This study is currently enrolling.
The purpose of this research study is to test how safe and well-tolerated treatment with the study drug is in combination with pembrolizumab and to find out more about the side-effects. The study aims to determine the following ...
NG-641-01: A Multicentre, Open-label, Non-randomised First in Human Study of NG-641, an Oncolytic Transgene Expressing Adenoviral Vector, in Patients With Metastatic or Advanced Epithelial Tumours (STAR)
This study is currently enrolling.
The purpose of this research study is to find out the following: (1) What effects, good and/or bad, treatment with NG-641 has on you and your cancer; (2) The amount of NG-641 that can be given and/or the best timing between dos ...
NRG-GY026: A PHASE II/III STUDY OF PACLITAXEL/CARBOPLATIN ALONE OR COMBINED WITH EITHER TRASTUZUMAB AND HYALURONIDASE-OYSK (HERCEPTIN HYLECTA) OR PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF (PHESGO) IN HER2 POSITIVE, STAGE I-IV ENDOMETRIAL SEROUS CARCINOMA OR CARCINOSARCOMA
This study is currently enrolling.
This study has public funding from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) in the United States Department of Health and Human Services. We do research studies to try to answer quest ...
Observational basket trial to predict response to immune checkpoint inhibitors across solid tumors using a live tumor diagnostic platform (CYBRID-02)
This study is currently enrolling.
Optimice-PCR: De-Escalation Of Therapy In Early-Stage TNBC Patients Who Achieve PCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy
This study is currently enrolling.
This study is being done to answer the following question: Among patients with early-stage TNBC who achieve a pCR after preoperative chemotherapy in combination with pembrolizumab, will observation after surgery be as effective ...